GIANT CELL ARTERITIS
Clinical trials for GIANT CELL ARTERITIS explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for GCA patients: drug may reduce relapses and steroid use
Disease control CompletedThis study tested a drug called secukinumab in 151 adults aged 50+ with newly diagnosed giant cell arteritis (GCA), a condition causing inflamed blood vessels. Participants were in remission and received either secukinumab or a placebo, along with a standard steroid taper. The go…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 28, 2026 23:52 UTC
-
New IV drug shows promise for inflammatory conditions in early trial
Disease control CompletedThis early-stage study tested an intravenous (IV) form of secukinumab in 65 adults with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR), two inflammatory conditions. The goal was to see how the drug moves through the body and whether it is safe. Participants received m…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC